(Source: Conatus Pharmaceuticals Inc) - Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis - - Emricasan Significantly Lowered Portal Pressure in Patients With Severe Portal Hypertension - SAN DIEGO, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late-breaking oral presentation at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco November 13-17, 2015. The presentation (#LB6), entitled 'Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and...
↧